title: Benefits versus risks of latest therapies in multiple sclerosis: a perspective review.
abstract: Disease-modifying treatments for multiple sclerosis (MS) have now been available for almost 20 years. Interferon β (IFN-β) products and glatiramer acetate (GA) were the first available options and are now considered first-line agents for the treatment of MS. These medications have several years of favorable safety data, but are not effective in completely controlling disease activity in all patients. Alternate medications with increased efficacy have been developed and identified; however, these newer medications have known or potential safety concerns which have prompted clinicians to view them as second-line agents. Highly efficacious and safe medications are continuously being searched for and developed; however, time is needed to establish the long-term safety of any new therapeutic agent. MS practitioners are faced with the clinical dilemma of treating patients with very safe modestly effective medications or using more efficacious and potentially riskier agents. The risk-benefit profile of every medication will have to be weighed carefully and clinicians will need to gage the risk tolerance of each patient in order to tailor treatment. This review will summarize benefits and risks of recently approved therapies in MS and will provide a perspective view on the placement of these medications within the MS treatment algorithm in the near future.
authors.affiliation: Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, 9500 Euclid Avenue, U-10, Cleveland, OH 44195, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Ontaneda
authors.affiliation: Neurology Service, Hospital Clínico Universitario San Carlos, Madrid, Spain.
authors.forename: Daniela
authors.initials: D
authors.lastname: Di Capua
keywords: disease-modifying agents; multiple sclerosis; risk/benefit; safety; toxicity
references.citation: Neurology. 2007 Oct 2;69(14):1391-403
references.pmid: 17761550
references.citation: Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101
references.pmid: 20061941
references.citation: J Neurol. 2004 Sep;251 Suppl 5:v50-v56
references.pmid: 15549356
references.citation: N Engl J Med. 2005 Jul 28;353(4):362-8
references.pmid: 15947080
references.citation: Eur J Neurol. 2012 Feb;19(2):307-11
references.pmid: 21899662
references.citation: Am J Pathol. 2012 Jan;180(1):267-74
references.pmid: 22152994
references.citation: J Neurol. 2006 Jan;253(1):98-108
references.pmid: 16044212
references.citation: Expert Rev Neurother. 2012 Mar;12(3):335-41
references.pmid: 22364332
references.citation: Expert Rev Clin Pharmacol. 2011 Sep;4(5):567-70
references.pmid: 22114884
references.citation: CNS Drugs. 2011 Jun 1;25(6):491-502
references.pmid: 21649449
references.citation: Nat Clin Pract Neurol. 2006 Jan;2(1):34-44
references.pmid: 16932519
references.citation: Nephrol Dial Transplant. 2011 Nov;26(11):3802-5
references.pmid: 21911597
references.citation: Ann Neurol. 2011 May;69(5):759-77
references.pmid: 21520239
references.citation: N Engl J Med. 2006 Mar 2;354(9):911-23
references.pmid: 16510745
references.citation: Ann Neurol. 2010 Sep;68(3):295-303
references.pmid: 20737510
references.citation: Mult Scler. 2008 May;14(4):494-9
references.pmid: 18208875
references.citation: J Neurol. 2008 Feb;255(2):231-8
references.pmid: 18283404
references.citation: Pharmacol Res. 2003 May;47(5):401-7
references.pmid: 12676514
references.citation: N Engl J Med. 2006 Mar 2;354(9):924-33
references.pmid: 16510746
references.citation: N Engl J Med. 2008 Oct 23;359(17):1786-801
references.pmid: 18946064
references.citation: Mult Scler. 2012 Sep;18(9):1278-89
references.pmid: 22307384
references.citation: N Engl J Med. 2005 Jul 28;353(4):369-74
references.pmid: 15947079
references.citation: Annu Rev Biochem. 2004;73:321-54
references.pmid: 15189145
references.citation: N Engl J Med. 2010 Feb 4;362(5):402-15
references.pmid: 20089954
references.citation: Clin Immunol. 2012 Jan;142(1):25-30
references.pmid: 21550857
references.citation: Neurol Clin. 2011 May;29(2):411-22
references.pmid: 21439450
references.citation: Neurology. 2012 Feb 7;78(6):436-7
references.pmid: 22282644
references.citation: J Neuroimmunol. 2004 Nov;156(1-2):3-9
references.pmid: 15465591
references.citation: Neurodegener Dis. 2008;5(1):27-31
references.pmid: 18075272
references.citation: Lancet. 2008 Jun 21;371(9630):2085-92
references.pmid: 18572078
references.citation: J Med Chem. 2004 Apr 8;47(8):2075-88
references.pmid: 15056005
references.citation: N Engl J Med. 2006 Mar 2;354(9):899-910
references.pmid: 16510744
references.citation: Neurology. 2011 Aug 9;77(6):573-9
references.pmid: 21795656
references.citation: Arthritis Rheum. 2005 Sep;52(9):2730-9
references.pmid: 16142756
references.citation: J Biol Chem. 2002 Jun 14;277(24):21453-7
references.pmid: 11967257
references.citation: Mult Scler Relat Disord. 2014 Sep;3(5):629-38
references.pmid: 26265275
references.citation: Pharmacol Ther. 2007 Jul;115(1):84-105
references.pmid: 17561264
references.citation: Br J Dermatol. 2003 Aug;149(2):363-9
references.pmid: 12932244
references.citation: Lancet Neurol. 2008 Jun;7(6):538-47
references.pmid: 18485317
references.citation: Expert Rev Neurother. 2004 Jul;4(4):571-80
references.pmid: 15853576
references.citation: Mult Scler. 2000 Apr;6(2):99-104
references.pmid: 10773855
references.citation: Neurology. 2012 Apr 3;78(14):1069-78
references.pmid: 22442431
references.citation: Mult Scler. 2011 Nov;17(11):1387-9
references.pmid: 21652609
references.citation: N Engl J Med. 2012 May 17;366(20):1870-80
references.pmid: 22591293
references.citation: Neurology. 2011 May 17;76(20):1697-704
references.pmid: 21576685
references.citation: N Engl J Med. 2005 Jul 28;353(4):375-81
references.pmid: 15947078
references.citation: Expert Rev Clin Immunol. 2012 Jan;8(1):63-72
references.pmid: 22149341
references.citation: Neurol Sci. 2009 Oct;30 Suppl 2:S167-70
references.pmid: 19882368
references.citation: J Immunol. 1997 Jul 1;159(1):167-74
references.pmid: 9200452
references.citation: Lancet Neurol. 2010 Apr;9(4):438-46
references.pmid: 20298967
references.citation: Lancet Neurol. 2009 Jun;8(6):545-59
references.pmid: 19446274
references.citation: Biochem Pharmacol. 1995 Sep 7;50(6):861-7
references.pmid: 7575649
references.citation: Brain. 2011 Mar;134(Pt 3):678-92
references.pmid: 21354971
references.citation: N Engl J Med. 2011 Oct 6;365(14):1293-303
references.pmid: 21991951
references.citation: N Engl J Med. 2012 Mar 15;366(11):1000-9
references.pmid: 22417253
references.citation: Neurology. 2005 Mar 22;64(6):987-91
references.pmid: 15781813
references.citation: Brain. 2010 Aug;133(Pt 8):2232-47
references.pmid: 20659956
references.citation: Transplantation. 2007 Oct 15;84(7):885-92
references.pmid: 17984842
references.citation: J Neuroimmunol. 2011 Jun;235(1-2):9-17
references.pmid: 21402415
references.citation: N Engl J Med. 2010 Feb 4;362(5):387-401
references.pmid: 20089952
references.citation: Am J Transplant. 2006 Dec;6(12):2912-21
references.pmid: 17061999
references.citation: Mult Scler. 2012 Feb;18(2):143-52
references.pmid: 22312009
references.citation: Neurology. 2006 Mar 28;66(6):894-900
references.pmid: 16567708